Patrick J. McEnany
Co-Founder, Chairman, President and Chief Executive Officer
Patrick J. McEnany has been Chief Executive Officer and a director of Catalyst since its formation in January 2002. In 2006 he became Chairman, President and Chief Executive Officer. From 1991 to April of 1997, Mr. McEnany was Chairman and Chief Executive Officer of Royce Laboratories, Inc. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as President of the wholly-owned Royce Laboratories subsidiary and Vice President of Corporate Development for Watson Pharmaceuticals, Inc. From 1993 through 1997, he also served as Vice Chairman and Director of the National Association of Pharmaceutical Manufacturers. He currently serves on the Board of Directors for the Jackson Memorial Hospital Foundation.
Steven R. Miller
Chief Operating Officer and Chief Scientific Officer
Steven R. Miller, PhD, is responsible for Catalyst’s product development program, which includes all aspects of chemistry and manufacturing controls, quality systems, contract operations, and development planning. Dr. Miller has 25 years of experience in the pharmaceutical and healthcare industries, joining Catalyst in 2007. Most recently he has managed Catalyst’s in-licensing of CPP-115 and Catalyst’s newest drug, Firdapse®, and taken these products through various preclinical and clinical development studies. Dr. Miller previously served as Executive Director for Research and Development Operations at Watson Pharmaceuticals and as Vice President of Research and Product Development at Royce Laboratories; he has also managed medical device development groups at Baxter Diagnostics and worked as an analytical chemist for the U.S. Food and Drug Administration. Dr. Miller received his doctorate in physical organic chemistry at the University of Miami; his work has been published in numerous technical and professional journals including Journal of Analytical Chemistry, Journal of the American Chemical Society, Journal of Medicinal Chemistry, and Chemical Communications.
Vice President, Chief Financial Officer and Treasurer
Alicia Grande, CPA, CMA, was appointed Vice President, Chief Financial Officer and Treasurer of Catalyst in December 2011, having joined the company as Corporate Controller and Chief Accounting Officer in 2007. Prior to that, she was Senior Director of Finance for The Hackett Group, Inc. (then known as Answerthink, Inc.), where she was responsible for all external and SEC financial reporting and served as head of the firm’s Sarbanes-Oxley Act compliance team. Ms. Grande previously was employed for more than 10 years by various public accounting firms, including Arthur Andersen, LLP. Ms. Grande earned a bachelor of science degree in business administration, with majors in accounting and finance, from Syracuse University and a master of accounting degree from Florida International University.
Chief Medical Officer
Gary Ingenito, MD, PhD, joined Catalyst in July 2015 as Chief Medical Officer. Dr. Ingenito brings more than 25 years of knowledge and experience in the field of pharmaceutical development: including drugs, biologics, and combination products. During this time, Dr. Ingenito held executive responsibilities for clinical research, regulatory, drug safety, and medical affairs at pharmaceutical companies and contract research organizations. Dr. Ingenito initially joined Sandoz Pharmaceuticals in the neuroendocrine group and progressed to become head of medical affairs. He spent 8 years at Otsuka Pharmaceuticals, overseeing the approval of anti-infective, cardiovascular, and central nervous system products. Dr. Ingenito has held positions at Corning-Besselaar, Angiotech Pharmaceuticals, Biotest Pharmaceuticals, and Boehringer-Ingelheim Pharmaceuticals. After obtaining his bachelor of arts degree from Johns Hopkins University, Dr. Ingenito earned his medical degree at Jefferson Medical College, and a doctor of philosophy degree from Thomas Jefferson University. He completed a post-graduate residency in neurology at the University of Miami, Jackson Memorial Hospital.
Daniel J. Brennan
Chief Commercial Officer
Daniel J. Brennan joined us in June 2018 as our Chief Commercial Officer. Mr. Brennan has over 20 years of experience in the pharmaceutical industry. Most recently, from October 2016 to May 2018, Mr. Brennan served as the Chief Operating Officer at Edge Therapeutics, where he was responsible for pre-commercialization activities of the company’s lead product targeting rare neurological conditions. Prior to joining Edge Therapeutics, from November 2015 to August 2016, Mr. Brennan served as Chief Operating Officer and Executive Vice President of Insys Therapeutics. Prior thereto from July 2009 to October 2015, Mr. Brennan held multiple leadership positions at Lundbeck U.S., including serving as Vice President and Group General Manager of Lundbeck’s U.S. Neurology Business Unit and Business Development group. Throughout his time in these positions, Lundbeck’s U.S. Neurology group launched four specialty orphan products. Prior to Lundbeck, Mr. Brennan was at Abbott Laboratories, where he served as Divisional Vice President and General Management of the Acute Care Hospital Business Unit. Previously, from 1997 to 2007, Mr. Brennan served in various sales, marketing and new product development roles with Eli Lilly and Company. Mr. Brennan holds a B.A. from the University of Notre Dame and M.B.A. from the Kellogg Graduate School of Business at Northwestern University.
Senior Vice President, Legal and Compliance
Brian Elsbernd joined Catalyst in February 2016 as the Senior Vice President of Legal and Compliance. Prior to joining Catalyst, Mr. Elsbernd was Senior Director of US Healthcare Compliance at Mallinckrodt Pharmaceuticals, a growing US specialty pharmaceutical business. From its inception, he led their healthcare compliance and business ethics program while also managing multiple other legal and business functions. Previously, Mr. Elsbernd was an associate at Proskauer Rose LLP, within its Health Care practice group, representing healthcare providers nationwide in matters pertaining to regulatory and administrative law, transactional matters, litigation, and reimbursement issues. Mr. Elsbernd earned his law degree from Saint Louis University School of Law and his undergraduate degree at the University of Illinois.